17
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      COVID-19 Pneumonia: Three Thoracic Complications in the Same Patient

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The most dreaded thoracic complications in patients with coronavirus disease 2019 (COVID-19) are acute pulmonary embolism and pulmonary fibrosis. Both the complications are associated with an increased risk of morbidity and mortality. While acute pulmonary embolism is not a rare finding in patients with COVID-19 pneumonia, the prevalence of pulmonary fibrosis remains unclear. Spontaneous pneumothorax is another possible complication in COVID-19 pneumonia, although its observation is rather uncommon. Herein, we present interesting computed tomography images of the first case of COVID-19 pneumonia that initially developed acute pulmonary embolism and subsequently showed progression toward pulmonary fibrosis and spontaneous pneumothorax.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found

          Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

          Summary Background In December, 2019, a pneumonia associated with the 2019 novel coronavirus (2019-nCoV) emerged in Wuhan, China. We aimed to further clarify the epidemiological and clinical characteristics of 2019-nCoV pneumonia. Methods In this retrospective, single-centre study, we included all confirmed cases of 2019-nCoV in Wuhan Jinyintan Hospital from Jan 1 to Jan 20, 2020. Cases were confirmed by real-time RT-PCR and were analysed for epidemiological, demographic, clinical, and radiological features and laboratory data. Outcomes were followed up until Jan 25, 2020. Findings Of the 99 patients with 2019-nCoV pneumonia, 49 (49%) had a history of exposure to the Huanan seafood market. The average age of the patients was 55·5 years (SD 13·1), including 67 men and 32 women. 2019-nCoV was detected in all patients by real-time RT-PCR. 50 (51%) patients had chronic diseases. Patients had clinical manifestations of fever (82 [83%] patients), cough (81 [82%] patients), shortness of breath (31 [31%] patients), muscle ache (11 [11%] patients), confusion (nine [9%] patients), headache (eight [8%] patients), sore throat (five [5%] patients), rhinorrhoea (four [4%] patients), chest pain (two [2%] patients), diarrhoea (two [2%] patients), and nausea and vomiting (one [1%] patient). According to imaging examination, 74 (75%) patients showed bilateral pneumonia, 14 (14%) patients showed multiple mottling and ground-glass opacity, and one (1%) patient had pneumothorax. 17 (17%) patients developed acute respiratory distress syndrome and, among them, 11 (11%) patients worsened in a short period of time and died of multiple organ failure. Interpretation The 2019-nCoV infection was of clustering onset, is more likely to affect older males with comorbidities, and can result in severe and even fatal respiratory diseases such as acute respiratory distress syndrome. In general, characteristics of patients who died were in line with the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia. Further investigation is needed to explore the applicability of the MuLBSTA score in predicting the risk of mortality in 2019-nCoV infection. Funding National Key R&D Program of China.
            • Record: found
            • Abstract: found
            • Article: not found

            Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography

            Summary In patients with severe clinical features of COVID-19 infection, the proportion of patients with acute pulmonary embolus was 23% (95% CI: 15%, 33%) on pulmonary CT angiography. Introduction Chest CT plays an important role in optimizing the management of patients with COVID-19 while also eliminating alternate diagnoses or added pathologies, particularly for acute pulmonary embolism (1). A few studies and isolated clinical cases of COVID-19 pneumonia with coagulopathy and pulmonary embolus have recently been published (2–4). The main objective of our study was to evaluate pulmonary embolus in association with COVID-19 infection using pulmonary CT angiography. Materials and Methods This retrospective study was approved by our institutional review board. It followed the ethical guidelines of the declaration of Helsinki. Written informed consent was waived. Three authors (F.G., J.B., P.C.) had access to the study data. No author has any conflict of interest to declare in relation to this study. Patients The inclusion criteria were consecutive adult patients (≥ 18 years old) with a RT-PCR diagnosis (NucleoSpin RNA Virus kit, Macherey-Nagel Inc., Bethlehem, PA, USA) of SARS-CoV-2 or a strong clinical suspicion of COVID-19 (fever and/or acute respiratory symptoms, exposure to an individual with confirmed SARS-CoV-2 infection) who underwent a chest CT scan between March 15 to April 14, 2020 at a single center. In patients with suspected or confirmed SARS-CoV-2 infection, chest CT scan was performed when clinical features of severe disease were present (e.g., requirement for mechanical ventilation [IMV]) or underlying comorbidities). Patients with non-contrast chest CT scans were excluded. CT Protocol Our routine protocol for patients with severe clinical features of COVID-19 infection was multidetector pulmonary CT angiography using 256 slice multi-detector CT (Revolution, GE Healthcare, Milwaukee, WI) after intravenous injection of 60 ml iodinated contrast agent (Iomeprol 400 Mg I/mL, Bracco Imaging, Milan, IT) at a flow rate of 4 mL/s, triggered on the main pulmonary artery. CT scan settings were 120 kVp, 80 x .625 mm, rotation time .28 s, average tube current 300 mA, pitch .992 and CTDIvol 4.28 mGy. Imaging Analysis. Chest CT scan pattern of COVID-19 and presence of pulmonary embolus were independently analyzed by two chest radiologists (J.B. and F.G. with 11 and 6 years of experience) on a PACS workstation (Carestream Health, Rochester, NY). Readers were blinded to patient status as well as clinical and biological features. In cases of discordance, a simultaneous reading to reach consensus was achieved. Statistical Analysis Comparisons between continuous variables were performed using Student t-test when distribution was normal. Comparison between categorical variables were performed using Pearson's chi-squared test or Fisher’s exact test. To determine the clinical factors associated with pulmonary embolus, we considered the CT extent of lesions, need for invasive mechanical ventilation, demographics, and the presence of comorbidities as potential independent variables in a logistic regression model. A P value of less than .05 indicated a significant difference. All analyses were performed with R version 3.4.4 (R Core Team 2017). Results Of 2003 patients diagnosed with COVID-19, 280 patients were hospitalized during the study period. Of these, 129 of 280 (46%) hospitalized patients underwent CT scan at an average of 9 ± 5 days after symptom onset. Twenty-nine patients had non-contrast chest CT due to contraindication to iodinated contrast or non-severe clinical features and thus were excluded. Finally, 100 patients with COVID-19 infection and severe clinical features were included were examined with contrast enhanced CT (Figure 1). The mean age of the included patients was 66 ± 13 years old, with 70 men and 30 women (Table; Appendix E1 [online]). Of 100 patients meeting inclusion criteria, 23 (23%, [95%CI, 15-33%]) patients had acute pulmonary embolism (Figure 2; Appendix E1 [online]). Patients with pulmonary embolus were more frequently in the critical care unit than those without pulmonary embolus (17 (74%) vs 22 (29%) patients, p<.001), required mechanical ventilation more often (15 (65%) versus 19 (25%) patients, p<.001) and had longer delay from symptom onset to CT diagnosis of pulmonary embolus (12 ± 6 versus 8 ± 5 days, p<.001), respectively (Table). In multivariable analysis, requirement for mechanical ventilation (OR = 3.8 IC95% [1.02 - 15], p=.049) remained associated with acute pulmonary embolus. Figure 1: Flow chart of the study. Figure 2: Pulmonary CT angiography of a 68 year old male. The CT scan was obtained 10 days after the onset of COVID-19 symptoms and on the day the patient was transferred to the intensive care unit. Axial CT images (lung windows) (a,b) show peripheral ground-glass opacities (arrow) associated with areas of consolidation in dependent portions of the lung (arrowheads). Interlobular reticulations, bronchiectasis (black arrow) and lung architectural distortion are present. Involvement of the lung volume was estimated to be between 25% and 50%. Coronal CT reformations (mediastinum windows) (c,d) show bilateral lobar and segmental pulmonary embolism (black arrows). Table. Patient Characteristics Discussion Our study points to a high prevalence of acute pulmonary embolism in patients with COVID-19 (23%, [95%CI, 15-33%]). Pulmonary embolus was diagnosed at mean of 12 days from symptom onset. Patients with pulmonary embolus were more likely require care in the critical care unit and to require mechanical ventilation than those without pulmonary embolus (Table). Current guidelines (1,5,6) recommend performing non-contrast chest CT to assess the COVID-19 CT pattern and its extension. However, prior reports suggested coagulopathy associated with COVID-19 infection [e.g. (2,3)]. Further, these patients have frequent risk factors for pulmonary embolus (e.g. mechanical ventilation, intensive care unit admission). Therefore, we routinely performed contrast enhanced CT for COVID-19 patients with severe clinical features to evaluate the lung parenchyma as well as to evaluate other complications that may result in respiratory distress. Our results showed frequent (23%) pulmonary embolus in patients with COVID-19. In multivariate analysis, pulmonary embolus was associated with invasive mechanical ventilation and male gender. Interestingly, extent of lesions was not a associated with pulmonary embolus. We acknowledge the preliminary nature of these findings, including its retrospective nature and limited sample size. Important clinical markers were not available that may explain or be associated with pulmonary embolus, including D-dimer (only 22 of 100 patients had D-dimer levels available). Nevertheless, our results suggest that patients with severe clinical features of COVID-19 may have associated acute pulmonary embolus. Therefore, the use of contrast enhanced CT rather than routine non-contrast CT may be considered for these patients. APPENDIX Appendix E1, Tables E1-E3, Figures E1-E2 (PDF)
              • Record: found
              • Abstract: found
              • Article: not found

              Pulmonary fibrosis secondary to COVID-19: a call to arms?

              As of May 6, 2020, nearly 3·7 million people have been infected and around 260 000 people have died from coronavirus disease 2019 (COVID-19) worldwide. 1 Almost all COVID-19-related serious consequences feature pneumonia. 2 In the first large series of hospitalised patients (n=138) with COVID-19 in Wuhan, China, chest CT showed bilateral ground glass opacities with or without consolidation and with lower lobe predilection in all patients. 3 In this series, 36 (26%) patients required intensive care, of whom 22 (61%) developed acute respiratory distress syndrome (ARDS). 3 The mechanisms through which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes lung damage are only partly known, but plausible contributors include a cytokine release syndrome triggered by the viral antigen, drug-induced pulmonary toxicity, and high airway pressure and hyperoxia-induced acute lung injury secondary to mechanical ventilation. To date, about 1·2 million people worldwide have recovered from COVID-19, but there remains concern that some organs, including the lungs, might have long-term impairment following infection (figure ). No post-discharge imaging or functional data are available for patients with COVID-19. Figure Lung CT of a patient with coronavirus disease 2019 (A) Images of peripheral mild ground glass opacities in the left lower lobe (arrow). (B) Three weeks later, at the same lung zones, the disease has rapidly progressed and fibrotic changes are now evident (arrows). Other strains of the coronavirus family, namely severe acute respiratory syndrome coronavirus (SARS-CoV; known as SARS) and Middle East respiratory syndrome coronavirus (MERS-CoV; known as MERS), are genetically similar to SARS-CoV-2 and cause pulmonary syndromes similar to COVID-19. At the end of the SARS epidemic in June, 2003, 8422 individuals were affected and 916 died; whereas MERS, which was first identified in April, 2012, has infected 2519 individuals worldwide to date, including 866 deaths. 4 The predominant CT abnormalities in patients with SARS included rapidly progressive ground glass opacities sometimes with consolidation. Reticular changes were evident approximately 2 weeks after symptom onset and persisted in half of patients beyond 4 weeks. 5 However, a 15-year follow-up study of 71 patients with SARS showed that interstitial abnormalities and functional decline recovered over the first 2 years following infection and then remained stable. At 15 years, 4·6% (SD 6·4%) of the lungs showed interstitial abnormality in patients who had been infected with SARS. 6 In patients with MERS, typical CT abnormalities included bilateral ground glass opacities, predominantly in the basal and peripheral lung zones. Follow-up outcomes are less well described in patients with MERS. In a study of 36 patients who had recovered from MERS, chest x-rays taken a median of 43 (range 32–320) days after hospital discharge showed abnormalities described as lung fibrosis in about a third of the patients. 7 Longer-term follow-up of patients who recovered from MERS has not been reported. Pulmonary fibrosis can develop either following chronic inflammation or as a primary, genetically influenced, and age-related fibroproliferative process, as in idiopathic pulmonary fibrosis (IPF). Pulmonary fibrosis is a recognised sequelae of ARDS. However, most follow-up studies—which have included both physiological measures and chest CT—have shown that persistent radiographic abnormalities after ARDS are of little clinical relevance and have become less common in the era of protective lung ventilation. 8 Available data indicate that about 40% of patients with COVID-19 develop ARDS, and 20% of ARDS cases are severe. 9 Of note, the average age of patients hospitalised with severe COVID-19 appears to be older than that seen with MERS or SARS, which is perhaps a consequence of wider community spread. In inflammatory lung disorders, such as those associated with autoimmune disease, advancing age is a risk factor for the development of pulmonary fibrosis. Given these observations, the burden of pulmonary fibrosis after COVID-19 recovery could be substantial. Progressive, fibrotic irreversible interstitial lung disease, which is characterised by declining lung function, increasing extent of fibrosis on CT, worsening symptoms and quality of life, and early mortality, 10 arises, with varying degrees of frequency, in the context of a number of conditions including IPF, hypersensitivity pneumonitis, autoimmune disease, and drug-induced interstitial lung disease. Although the virus is eradicated in patients who have recovered from COVID-19, the removal of the cause of lung damage does not, in itself, preclude the development of progressive, fibrotic irreversible interstitial lung disease. Furthermore, even a relatively small degree of residual but non-progressive fibrosis could result in considerable morbidity and mortality in an older population of patients who had COVID-19, many of whom will have pre-existing pulmonary conditions. At present, the long-term pulmonary consequences of COVID-19 remains speculative and should not be assumed without appropriate prospective study. Nonetheless, given the huge numbers of individuals affected by COVID-19, even rare complications will have major health effects at the population level. It is important that plans are made now to rapidly identify whether the development of pulmonary fibrosis occurs in the survivor population. By doing this, we can hope to deliver appropriate clinical care and urgently design interventional trials to prevent a second wave of late mortality associated with this devastating pandemic.

                Author and article information

                Journal
                Diagnostics (Basel)
                Diagnostics (Basel)
                diagnostics
                Diagnostics
                MDPI
                2075-4418
                20 July 2020
                July 2020
                : 10
                : 7
                : 498
                Affiliations
                [1 ]Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy; davide.farina@ 123456unibs.it (D.F.); roberto.maroldi@ 123456unibs.it (R.M.)
                [2 ]Department of Clinical and Experimental Sciences, University of Brescia, UOC 2° Medicina, ASST Spedali Civili of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy; carloaggiusti@ 123456gmail.com (C.A.); marialorenza.muiesan@ 123456unibs.it (M.L.M.)
                Author notes
                Author information
                https://orcid.org/0000-0002-4761-2923
                Article
                diagnostics-10-00498
                10.3390/diagnostics10070498
                7399854
                32698424
                a486164f-90c8-4fe9-9994-8c9923773c14
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 02 July 2020
                : 17 July 2020
                Categories
                Interesting Images

                covid-19,computed tomography,acute pulmonary embolism,pulmonary fibrosis,pneumothorax

                Comments

                Comment on this article

                Related Documents Log
                scite_

                Similar content249

                Cited by5

                Most referenced authors636